Volume 2, Issue 2 , Pages 88-92, April 2009
Decreasing procedural pain over time of left prefrontal rtms for depression: Initial results from the open-label phase of a multisite trial (OPT-TMS)
Background
There is much interest in whether daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) over several weeks may become a clinically useful antidepressant treatment. Although rTMS appears largely safe, many patients report that this procedure is somewhat painful, which may restrict its ultimate appeal and use. We analyzed interim results from the open-label phase of a multisite randomized trial of rTMS as a treatment for depression to investigate whether the procedural pain of left prefrontal rTMS changes over time.
Methods
Patients with unipolar depression who had failed to respond during at least 3 weeks of the sham-controlled double-masked rTMS were then offered 3 more weeks (15 sessions) of open-label rTMS. Retrospective pain ratings and state emotional factors from 20 subjects were assessed with the use of visual analog scales (VAS) recorded on computers before and after each treatment (289 sessions).
Results
Over the 15 treatment sessions, subjective reports of the painfulness of rTMS decreased 48% from baseline. This reduction, although greatest in the first few days, continued steadily (average 2.11 points per session) over the 3 weeks of treatment. The analysis found a significant effect for rTMS-session (P < .0001) on rTMS-procedural pain over and above changes in subjective emotional states.
Conclusions
The procedural pain of left, prefrontal rTMS decreases over time, apparently independently of other emotional changes. Because rTMS scalp pain may decline over time, physicians and patients may decide to continue treatment despite initial discomfort. These observational data can be better tested once the data from the blinded phase of the trial becomes available.
Keywords: transcranial magnetic stimulation, pain, discomfort, virtual analog scale
To access this article, please choose from the options below
The study was funded by National Institute of Mental Health (NIMH) Grants R01MH069887, R01MH069896, R01MH069895, R01MH069886, and R01MH069929; and equipment support was provided by Neuronetics, Inc. Additional support for the MUSC Brain Stimulation Laboratory comes from the Stanley Foundation, the National Alliance for Research on Schizophrenia and Depression (NARSAD), NIMH Grant K08MH070615 (Dr Nahas), and NINDS Grant K23NS050485 (Dr Borckardt).
Conflicts of Interest: MUSC holds several TMS-related patents. Drs George and Sackeim are advisory board members for Neuronetics, Inc.
PII: S1935-861X(08)00333-1
doi:10.1016/j.brs.2008.09.001
© 2009 Elsevier Inc. All rights reserved.
Volume 2, Issue 2 , Pages 88-92, April 2009
